11 April 2025

Argent BioPharma Ltd.
(Argent BioPharma or the Company)

Results of Shareholder's General Meeting

Argent BioPharma would like to announce the results from the Company's General Meeting of Shareholders held today, Friday, 11 April 2025, in accordance with ASX Listing Rule 3.13.2.

The Company confirms that all motions put to the meeting were voted by poll, with all resolutions carried. Details of the proxy voting and voting outcomes for all motions put to the meeting are set out in the attached.

—Ends—

Authorised for release by the board of directors, for further information please contact:

Argent BioPharma
Roby Zomer
CEO & Managing Director
+61 8 6555 2950
info@argentbiopharma.com

Argent BioPharma
Rowan Harland
Company Secretary
+61 8 6555 2950
info@argentbiopharma.com

About Argent BioPharma

Argent BioPharma Limited (ASX: RGT) is an innovative clinical-stage biopharmaceutical company specialising in neuroimmunology and advanced nanomedicine. By leveraging the Neuro-Immune Modulatory (NIM) System, Argent BioPharma's robust pipeline—including CannEpil®, CogniCann®, and CimetrA®—targets CNS disorders and immune-related conditions. With a commitment to science-driven innovation, Argent BioPharma is shaping the future of cannabinoid-based therapeutics and neuroimmune modulation.

Follow us through our social media channels:
LinkedIn: Argent BioPharma
Twitter: @ArgentBioPharma
Facebook: Argent BioPharma

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result
Resolution	**Resolution Type**	**For**	**Against**	**Proxy's Discretion**	**Abstain**	**For**	**Against**	**Abstain***	**Carried / Not Carried**
1 Ratification of prior issue of Placement Shares – Listing Rule 7.1	Ordinary	24,019,025 99.76%	51,805 0.22%	5,663 0.02%	6,035	24,031,696 99.78%	51,805 0.22%	6,035	Carried
2 Ratification of prior issue of Placement Shares – Listing Rule 7.1A	Ordinary	24,018,959 99.76%	51,815 0.22%	5,719 0.02%	6,035	24,031,686 99.78%	51,815 0.22%	6,035	Carried
3 Ratification of prior issue of Tranche 1 Placement Warrants	Ordinary	24,020,244 99.76%	52,053 0.22%	5,569 0.02%	4,662	24,032,821 99.78%	52,053 0.22%	4,662	Carried
4 Approval to issue Tranche 2 Placement Shares and Warrants	Ordinary	24,018,906 99.76%	53,501 0.22%	5,469 0.02%	4,652	24,031,383 99.78%	53,501 0.22%	4,652	Carried
5 Approval to issue Corporate Advisor Warrants	Ordinary	27,400,911 99.79%	53,503 0.19%	6,479 0.02%	1,621,635	27,414,398 99.81%	53,503 0.19%	1,621,635	Carried
6 Ratification of prior issue of Shares to Mercer	Ordinary	28,993,639 99.80%	52,611 0.18%	6,825 0.02%	29,453	29,007,472 99.82%	52,611 0.18%	29,453	Carried
7 Ratification of prior issue of October Placement Shares	Ordinary	29,020,174 99.80%	52,116 0.18%	5,495 0.02%	4,743	29,032,677 99.82%	52,116 0.18%	4,743	Carried
8 Approval to issue Consultant Options	Ordinary	28,444,185 99.69%	80,145 0.28%	7,469 0.03%	2,795	28,458,662 99.72%	80,145 0.28%	2,795	Carried

Resolution	Type	For	Against	Abstain*		For	Against		Result
9 Approval to issue Consultant Options to A5 invest LLC	Ordinary	23,994,937 99.75%	55,030 0.23%	5,642 0.02%	26,919	24,007,587 99.77%	55,030 0.23%	26,919	Carried
10 Approval to issue Shares and Warrants to Oak Capital	Ordinary	20,645,235 99.69%	55,199 0.27%	8,279 0.04%	3,097	20,660,522 99.73%	55,199 0.27%	3,097	Carried
11 Approval of grant of Potential Termination Benefits to Roby Zomer	Ordinary	22,044,246 99.42%	123,340 0.56%	5,469 0.02%	6,909,473	22,056,723 99.44%	123,340 0.56%	6,909,473	Carried
12 Approval to increase Maximum Securities under the Company's Employee Securities Incentive Plan	Ordinary	28,957,186 99.57%	118,754 0.41%	5,924 0.02%	664	28,963,118 99.59%	118,754 0.41%	7,664	Carried

* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.